Skip to main content
Netramark Holdings Inc. logo

Netramark Holdings Inc. — Investor Relations & Filings

Ticker · AIAI ISIN · CA64119M1059 LEI · 391200VOK8WHERIX0Q06 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 234 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CA Canada
Listing CSE AIAI

About Netramark Holdings Inc.

https://www.netramark.com/

Netramark Holdings Inc. develops and deploys advanced Artificial Intelligence (AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry, focusing on optimizing clinical trial design and outcomes. Its core product, NetraAI, is an AI platform powered by the proprietary Attractor AI algorithm. NetraAI analyzes complex, multimodal clinical trial datasets to uncover hidden patient correlations and causal factors, providing high clarity and explainability. The platform delivers AI-powered insights to trial sponsors, clinical research organizations, and biotechnology companies. These insights are used to inform protocol design, identify optimal patient subpopulations, determine effective dosage, enhance enrichment strategies, and improve inclusion/exclusion criteria, thereby increasing effect sizes and minimizing clinical trial risks.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 15% confidence The document is a corporate news release announcing high‐grade geochemical sampling results at a gold exploration project. It does not present quarterly or annual financial results (ER, IR, 10-K), management discussion (MDA), an investor slide deck (IP), AGM materials (AGM-R), or any other specific regulatory form. It is an operational update on exploration results, which does not match any specialized category. Therefore it falls into the fallback category for general regulatory announcements (RNS).
2026-04-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release commenting on a U.S. Executive Order related to accelerating treatments for serious mental illness and the need for regulatory-grade trial design in psychedelic drug development. It discusses the company's views on regulatory science, clinical trial design, and their AI platform's capabilities. There are no financial statements, no detailed financial performance data, no earnings results, no management or board changes, no voting results, no legal proceedings, no merger or acquisition activity, and no regulatory certifications or attestations. The document is informational and promotional in nature, typical of a press release or general regulatory announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other specific financial or governance filing. Given the content and style, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and company statements that do not fit other categories. The document length (8310 characters) and content confirm it is not a brief announcement of a report but a standalone press release.
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from an auditor firm confirming their appointment as auditor for Tempramed Technologies Ltd., referencing a change of auditor notice filed under National Instrument 51-102. The content is a certification or confirmation letter related to an auditor change, not a full audit report or annual report. The document length is short (672 characters), and it serves as an attestation rather than containing financial data or audit results. According to the rules, such certification letters should be classified as Regulatory Filings (RNS).
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release commenting on a U.S. Executive Order related to accelerating treatments for serious mental illness and the need for regulatory-grade trial design in psychedelic development. It discusses the company's views on regulatory science, clinical trial design, and their AI platform's capabilities. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no merger or acquisition details, and no direct report filings. The document is a public announcement or commentary rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other specific report type. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and public statements that do not fit other categories. The document length (8310 characters) and content support this classification with high confidence.
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing the publication of a peer-reviewed scientific article in an external journal. It does not present financial results, corporate governance changes, or any of the other specific report types (e.g., Annual Report, Earnings Release, Investor Presentation). It is not announcing a financial report itself but rather a scientific publication, so it falls into the miscellaneous regulatory announcement category.
2026-04-10 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 95% confidence The document is a pricing supplement for 'NBC Auto Callable Contingent Income Note Securities' issued by the National Bank of Canada. It details the specific terms, investment highlights, risk factors, and return calculations for a structured financial product. This type of document is a standard offering document for structured notes, which falls under the category of capital and financing updates as it relates to the issuance of debt-linked securities.
2026-02-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.